Loading...
OTCM
ATXI
Market cap1mUSD
Jul 10, Last price  
0.32USD
1D
-3.39%
1Q
-29.16%
IPO
-100.00%
Name

Avenue Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ATXI chart
P/E
—
P/S
0.75
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.27%
Rev. gr., 5y
%
Revenues
1m
00000000001,404,000
Net income
-3m
L-75.03%
-5,226,000-3,177,000-12,258,000-21,548,000-25,908,000-5,151,000-3,731,000-3,552,000-10,377,000-11,652,000-2,909,000
CFO
-2m
L-79.69%
-895,000-1,632,000-6,802,000-18,216,000-26,259,000-4,613,000-3,750,000-7,596,000-9,451,000-9,026,000-1,833,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
URL
https://avenuetx.com/
IPO date
Jun 27, 2017
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT